Andrew Ko

Andrew Ko is a Professor in the Division of Hematology/Oncology at the University of California San Francisco (UCSF). His primary clinical and research interests focus on gastrointestinal malignancies, particularly pancreatic and gastroesophageal cancers. He has led numerous clinical trials evaluating novel therapies, including molecular targeted agents and immunotherapies, supported by the National Cancer Institute (NCI), NIH, and industry collaborators.

• Chair, NCI Pancreatic Cancer Task Force
• Associate Editor, Journal of Clinical Oncology
• Member, NCCN Pancreatic Cancer Guidelines Committee
• Chief Medical Officer, UCSF Pancreas Center

Ko’s research emphasizes identifying biomarkers (tissue- and blood-based) to predict prognosis and therapy response. He has received multiple awards, including the NCI Cancer Clinical Investigator Team Leadership Award and ASCO Career Development Award. His educational background includes a Sc.B. in Applied Mathematics/Biology from Brown University and an M.D. from Johns Hopkins School of Medicine.

Scientific awards received include National Merit Scholarship, Sigma Xi associate membership, Alpha Omega Alpha honors, and recognition for clinical and teaching excellence. His work spans translational research, clinical trial design, and real-world data integration in oncology.